文献速递先天性心脏病外科

大多数儿童Fontan患者移植后生存率优异

The majority of pediatric Fontan patients have excellent post-transplant survival.
PubMed 文献 · J Thorac Cardiovasc Surg · 2023-09-27

该研究利用美国器官共享网络和儿科健康信息系统,识别2005至2022年间接受心脏移植的18岁以下Fontan患者241例,分析移植后生存情况。结果显示1年和5年生存率分别为89%和74%,无失代偿患者分别为93%和88%;失代偿是移植后生存较差的预测因素(HR 2.47),而移植时年龄较大预测生存更优(HR 0.89/年)。

要点

  • 儿童Fontan患者移植后1年生存率为89%,5年生存率为74%。
  • 移植时无失代偿者1年及5年生存率分别为93%和88%。
  • 失代偿预测移植后生存较差,HR为2.47。

核心结论

  • 儿童Fontan患者移植后结局良好,但早期死亡率仍较高;对于移植时无失代偿且无终末器官疾病的患者(占队列>63%),早期死亡得以避免,移植后生存优异且与所有儿童移植相似。

研究设计与样本

  • 研究利用美国器官共享网络和儿科健康信息系统,识别2005年至2022年间接受心脏移植的18岁以下Fontan患者241例进行回顾性分析。

主要发现

  • 移植时中位年龄9岁(四分位距5-12岁),中位等待时间107天(37-229天),32个中心的中位病例量为8例(3-11例)。
  • 45%(107例)的受者为1A/1初始登记状态,28%(64例)存在功能受损,4%(10例)使用通气,8%(18例)使用心室辅助装置,25%(59例)有肝功能障碍,6%(15例)有肾功能障碍,9%(21例)依赖全肠外营养。
  • 术后中位住院时间24天(14-46天),院内死亡率为7%。
  • Kaplan-Meier分析显示1年和5年生存率分别为89%(95%CI 85-94)和74%(95%CI 81-86);无失代偿患者(n=154)的1年和5年生存率分别为93%(95%CI 88-97)和88%(95%CI 82-94)。
  • 失代偿患者院内死亡率高于无失代偿患者(11% vs 4%,P = .023);多变量分析显示失代偿预测移植后生存较差(HR 2.47;95%CI 1.16-5.22;P = .018),而移植时年龄较大预测移植后生存更优(HR 0.89/年;95%CI 0.80-0.98;P = .019)。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Many pediatric Fontan patients require heart transplant, but this cohort is understudied given the difficulty in identifying these patients in national registries. We sought to characterize survival post-transplant in a large cohort of pediatric patients undergoing the Fontan. METHODS: The United Network for Organ Sharing and Pediatric Health Information System were used to identify Fontan heart transplant recipients aged less than 18 years (n = 241) between 2005 and 2022. Decompensation was defined as the presence of extracorporeal membrane oxygenation, ventilation, hepatic/renal dysfunction, paralytics, or total parenteral nutrition at transplant. RESULTS: Median age at transplant was 9 (interquartile range, 5-12) years. Median waitlist time was 107 (37-229) days. Median volume across 32 center was 8 (3-11) cases. Approximately half (n = 107, 45%) of recipients had 1A/1 initial listing status. Sixty-four patients (28%) were functionally impaired at transplant, 10 patients (4%) were ventilated, and 18 patients (8%) had ventricular assist device support. Fifty-nine patients (25%) had hepatic dysfunction, and 15 patients (6%) had renal dysfunction. Twenty-one patients (9%) were dependent on total parenteral nutrition. Median postoperative stay was 24 (14-46) days, and in-hospital mortality was 7%. Kaplan-Meier analysis showed 1- and 5-year survivals of 89% (95% CI, 85-94) and 74% (95% CI, 81-86), respectively. Kaplan-Meier of Fontan patients without decompensation (n = 154) at transplant demonstrated 1- and 5-year survivals of 93% (95% CI, 88-97) and 88% (95% CI, 82-94), respectively. In-hospital mortality was higher in decompensated patients (11% vs 4%, P = .023). Multivariable analysis showed that decompensation predicted worse post-transplant survival (hazard ratio, 2.47; 95% CI, 1.16-5.22; P = .018), whereas older age at transplant predicted superior post-transplant survival (hazard ratio, 0.89/year; 95% CI, 0.80-0.98; P = .019). CONCLUSIONS: Pediatric Fontan post-transplant outcomes are promising, although early mortality remains high. For nondecompensated pediatric patients at transplant without end-organ disease (>63% of cohort), early mortality is circumvented and post-transplant survival is excellent and similar to all pediatric transplantation.

来源:J Thorac Cardiovasc Surg,查看原文。版权归原作者所有。

引用

  1. Kulshrestha K, Greenberg JW, Kennedy JT, et al. The majority of pediatric Fontan patients have excellent post-transplant survival. J Thorac Cardiovasc Surg. 2023. PMID: 37774778. doi:10.1016/j.jtcvs.2023.09.044

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。